Erlotinib Plus Ramucirumab Show Promising Activity in EGFR+ Lung Cancer

November 26, 2019

Zofia Piotrowska, MD, MHS, a medical oncologist at Massachusetts General Hospital and an instructor at Harvard Medical School, discusses the results from the phase III RELAY trial that investigated first-generation EGFR inhibitor erlotinib plus the VGEF-directed antibody ramucirumab in patients with EGFR-mutant lung cancer.<br /> &nbsp;

Zofia Piotrowska, MD, MHS, a medical oncologist at Massachusetts General Hospital and an instructor at Harvard Medical School, discusses the results from the phase III RELAY trial that investigated first-generation EGFR inhibitor erlotinib (Tarceva) plus the VEGF-directed antibody ramucirumab (Cyramza) in patients withEGFR-mutant lung cancer.

The results were presented at the 2019 ASCO Annual Meeting, and the trial was positive. Erlotinib plus ramucirumab led to an improvement in progression-free survival compared with erlotinib monotherapy. However, Piotrowska says it remains to be seen how this combination regimen should be incorporated into the current treatment landscape for patients withEGFR-mutant lung cancer. Currently, osimertinib (Tagrisso) is the standard comparator arm for trials like RELAY.